SCHEMBL8079376

SCHEMBL8079376

COc1cc(NC(=O)c2ccc([N+](C)=O)cc2)cc(OC)c1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 8/20 0.74
RAB9A P51151 7/20 0.74
SMN1; SMN2 Q16637 5/20 0.74
KMT2A Q03164 5/20 0.74
TP53 P04637 4/20 0.74
MEN1 O00255 4/20 0.74
ALDH1A1 P00352 3/20 0.74
CYP1A2 P05177 1/20 0.74
CYP3A4 P08684 1/20 0.74
GAA P10253 1/20 0.74
CYP2D6 P10635 1/20 0.74
CYP2C9 P11712 1/20 0.74
CYP2C19 P33261 1/20 0.74
HTT P42858 1/20 0.68
PLAU P00749 2/20 0.59
PLG P00747 1/20 0.57
ALOX15 P16050 1/20 0.57
PKM P14618 1/20 0.56
NAMPT P43490 1/20 0.53
NLRP3 Q96P20 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31680508 0.89 NPC1 (0.93) NPC1RAB9ASMN1; SMN2KMT2ATP53
SCHEMBL4248472 0.88 KMT2A (0.70) NPC1RAB9ASMN1; SMN2KMT2ATP53
SCHEMBL4248077 0.85 NPC1 (1.00) NPC1RAB9ASMN1; SMN2KMT2ATP53
SCHEMBL1918108 0.83 NPC1 (0.81) NPC1RAB9ASMN1; SMN2KMT2ATP53
SCHEMBL29420092 0.83 NPC1 (0.81) NPC1RAB9ASMN1; SMN2KMT2ATP53
SCHEMBL12218147 0.81 RAB9A (0.79) NPC1RAB9ASMN1; SMN2KMT2ATP53
SCHEMBL28187512 0.81 RAB9A (1.00) NPC1RAB9ASMN1; SMN2KMT2ATP53
SCHEMBL7296804 0.80 SMN1; SMN2 (0.77) NPC1RAB9ASMN1; SMN2KMT2ATP53
SCHEMBL12218328 0.77 MEN1 (0.60) NPC1RAB9ASMN1; SMN2KMT2ATP53
SCHEMBL5426350 0.77 NPC1 (0.82) NPC1RAB9ASMN1; SMN2KMT2ATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009016088-A1 THE USE OF BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2009-02-05 WO disclosed